Roche inks $83M iPSC pact with Cellular Dynamics

Roche ($RHHBY) has inked a collaboration deal with Madison, WI-based Cellular Dynamics for a supply of induced pluripotent stem cell-derived iCell products that can be used to ID new drug candidates. The deal is worth up to $83 million for CDI. "Our partnerships with established leaders in the pharmaceutical industry, now including Roche, demonstrate that CDI products are increasingly becoming important tools for efficient drug discovery," says CDI CEO Kaz Hirao. "This agreement is the largest single collaboration for CDI to date." Release

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.